全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用：99美元
投递稿件

查看量下载量

相关文章

更多...
PLOS ONE  2014 

Health Outcomes and Cost Impact of the New WHO 2013 Guidelines on Prevention of Mother-to-Child Transmission of HIV in Zambia

DOI: 10.1371/journal.pone.0090991

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background Countries are currently progressing towards the elimination of new paediatric HIV infections by 2015. WHO published new consolidated guidelines in June 2013, which now recommend either ‘Antiretroviral drugs (ARVs) for women living with HIV during pregnancy and breastfeeding (Option B)’ or ‘Lifelong antiretroviral therapy (ART) for all pregnant and breastfeeding women living with HIV (Option B+)’, while de facto phasing out Option A. This study examined health outcomes and cost impact of the shift to WHO 2013 recommendations in Zambia. Methods A decision analytic model was developed based on the national health system perspective. Estimated risk and number of cases of HIV transmission to infants and to serodiscordant partners, and proportions of HIV-infected pregnant women with CD4 count of ≤350 cells/mm3 to initiate ART were compared between 2010 Option A and the 2013 recommendations. Total costs of prevention of mother-to-child transmission of HIV (PMTCT) services per annual cohort of pregnant women, incremental cost-effectiveness ratio (ICER) per infection averted and quality-adjusted life-year (QALY) gained were examined. Results Our analysis suggested that the shift from 2010 Option A to the 2013 guidelines would result in a 33% reduction of the risk of HIV transmission among exposed infants. The risk of transmission to serodiscordant partners for a period of 24 months would be reduced by 72% with ‘ARVs during pregnancy and breastfeeding’ and further reduced by 15% with ‘Lifelong ART’. The probability of HIV-infected pregnant women to initiate ART would increase by 80%. It was also suggested that while the shift would generate higher PMTCT costs, it would be cost-saving in the long term as it spares future treatment costs by preventing infections in infants and partners. Conclusion The shift to the WHO 2013 guidelines in Zambia would positively impact health of family and save future costs related to care and treatment.

 References

[1]  De Cock KM, Fowler MG, Mercier E, de Vincenzi I, Saba J, et al. (2000) Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 283: 1175–1182. doi: 10.1001/jama.283.9.1175
[2]  WHO (2010) Antiretroviral drugs for treating pregnant women and preventing HIV infections in infants: recommendations for a public health approach. Geneva, Switzerland: WHO.
[3]  UNAIDS (2011) Global plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive. Geneva: UNAIDS.
[4]  UNAIDS (2013) Global report: UNAIDS report on the global AIDS epidemic 2013. Geneva: UNAIDS.
[5]  WHO (2012) Programmatic update: use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Geneva, Switzerland: WHO.
[6]  WHO (2013) Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva, Switzerland: WHO.
[7]  Mugo NR, Med M, Heffron R, Donnell D, Wald A, et al. (2011) Increased risk of HIV-1 transmission in pregnancy: a prospective study among African HIV-1 serodiscordant couples. AIDS 25: 1887–1895. doi: 10.1097/qad.0b013e32834a9338
[8]  Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493–505. doi: 10.1056/nejmoa1105243
[9]  Marazzi MC, Palombi L, Nielsen-Saines K, Haswell J, Zimba I, et al. (2011) Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes. AIDS 25: 1611–1618. doi: 10.1097/qad.0b013e3283493ed0
[10]  Ministry of Health Zambia (2012) Zambia country report: monitoring the declaration of committment on HIV and AIDS and the Universal Access. Lusaka: Ministry of Health Zambia.
[11]  Zambia (2012) Business case for an improved eMTCT protocol in Zambia - Moving to Option B+. Lusaka, Zambia: Available: http://emtct-iatt-v2.org.php54-1.dfw1-2.？websitetestlink.com/wp-content/uploads/2？013/02/Zambia-B+-Business-Case-Jan132.pd？f Accessed 2013 Dec 28.
[12]  UNAIDS Reference Group on Estimates Modelling and Projections (2011) Working Paper on Mother-to-Child HIV Transmission Rates for use in Spectrum.
[13]  Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, et al. (2010) Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 375: 2092–2098. doi: 10.1016/s0140-6736(10)60705-2
[14]  Hallett TB, Baeten JM, Heffron R, Barnabas R, de Bruyn G, et al. (2011) Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med 8: e1001123. doi: 10.1371/journal.pmed.1001123
[15]  Reynolds SJ, Makumbi F, Nakigozi G, Kagaayi J, Gray RH, et al. (2011) HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS 25: 473–477. doi: 10.1097/qad.0b013e3283437c2b
[16]  Attia S, Egger M, Muller M, Zwahlen M, Low N (2009) Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 23: 1397–1404. doi: 10.1097/qad.0b013e32832b7dca
[17]  Carter RJ, Dugan K, El-Sadr WM, Myer L, Otieno J, et al. (2010) CD4+ cell count testing more effective than HIV disease clinical staging in identifying pregnant and postpartum women eligible for antiretroviral therapy in resource-limited settings. J Acquir Immune Defic Syndr 55: 404–410. doi: 10.1097/qai.0b013e3181e73f4b
[18]  Central Statistical Office, Ministry of Health Zambia, Tropical Diseases Research Centre, University of Zambia, Macro International Inc (2009) Zambia Demographic and Health Survey 2007. Maryland, USA: CSO and Macro International Inc.
[19]  United Nations (2010) UN Data. Available: http://data.un.org/Search.aspx?q=annual+？number+of+birth Accessed 2012 Sep 15.
[20]  Ishikawa N, Shimbo T, Miyano S (2011) Costing Tool for Elimination Initiative (CTEI) From costing to planning: a tool to support the initiative for elimination of new paediatric HIV infections and congenital syphilis and improvement of the health and survival of mothers and infants. National Center for Global Health and Medicine (NCGM), Asia-Pacific United Nations Task Force for the Prevention of Parents-to-Child Transmission of HIV, and Pan American Health Organization (PAHO): Available: http://www.eptctasiapacific.org/funding-？resource-needs.
[21]  Clinton Health Access Initiative (2012) Antiretroviral (ARV) ceiling price list. Clinton Health Access Initiative: Available: http://www.clintonhealthaccess.org/news-？and-information/ARV-Ceiling-Price-List-M？ay-2012 Accessed 2012 Sep 10.
[22]  WHO Global price reporting mechanism. Geneva: Available: http://www.who.int/hiv/amds/gprm/en/inde？x.html. Accessed 2012 Sep 10.
[23]  Clinton Foundation (2009) HIV/AIDS diagnostic pricing outlook. Available: http://www.who.int/hiv/topics/treatment/？costing_clinton_diagnostic.pdf. Accessed 2012 Aug 15.
[24]  WHO Choosing interventions that are cost effective (WHO-CHOICE). Geneva: Available: http://www.who.int/choice/costs/en/index？.html Accessed 2012 Sep 17.
[25]  Soorapanth S, Sansom S, Bulterys M, Besser M, Theron G, et al. (2006) Cost-effectiveness of HIV rescreening during late pregnancy to prevent mother-to-child HIV transmission in South Africa and other resource-limited settings. J Acquir Immune Defic Syndr 42: 213–221. doi: 10.1097/01.qai.0000214812.72916.bc
[26]  Farnham PG, Gopalappa C, Sansom SL, Hutchinson AB, Brooks JT, et al. (2013) Updates of lifetime costs of care and quality-of-life estimates for HIV-infected persons in the United States: late versus early diagnosis and entry into care. J Acquir Immune Defic Syndr 64: 183–189. doi: 10.1097/qai.0b013e3182973966
[27]  WHO (2003) Guide to cost-effectiveness analysis. Geneva.
[28]  World Bank (2013) GDP per capita (current US$). Washington DC: Available: http://data.worldbank.org/indicator/NY.G？DP.PCAP.CD Accessed 2013 Dec 5.
[29]  Robberstad B, Evjen-Olsen B (2010) Preventing mother to child transmission of HIV with highly active antiretroviral treatment in Tanzania–a prospective cost-effectiveness study. J Acquir Immune Defic Syndr 55: 397–403. doi: 10.1097/qai.0b013e3181eef4d3
[30]  Orlando S, Marazzi MC, Mancinelli S, Liotta G, Ceffa S, et al. (2010) Cost-effectiveness of using HAART in prevention of mother-to-child transmission in the DREAM-Project Malawi. J Acquir Immune Defic Syndr 55: 631–634. doi: 10.1097/qai.0b013e3181f9f9f5
[31]  Shah M, Johns B, Abimiku A, Walker DG (2011) Cost-effectiveness of new WHO recommendations for prevention of mother-to-child transmission of HIV in a resource-limited setting. AIDS 25: 1093–1102. doi: 10.1097/qad.0b013e32834670b9
[32]  Kuznik A, Lamorde M, Hermans S, Castelnuovo B, Auerbach B, et al. (2012) Evaluating the cost-effectiveness of combination antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Uganda. Bull World Health Organ 90: 595–603. doi: 10.2471/blt.11.095430
[33]  Binagwaho A, Pegurri E, Drobac PC, Mugwaneza P, Stulac SN, et al. (2013) Prevention of Mother-To-Child Transmission of HIV: Cost-Effectiveness of Antiretroviral Regimens and Feeding Options in Rwanda. PLoS One 8: e54180. doi: 10.1371/journal.pone.0054180
[34]  Ciaranello AL, Perez F, Engelsmann B, Walensky RP, Mushavi A, et al. (2013) Cost-effectiveness of World Health Organization 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe. Clin Infect Dis 56: 430–446. doi: 10.1093/cid/cis858
[35]  Fasawe O, Avila C, Shaffer N, Schouten E, Chimbwandira F, et al. (2013) Cost-effectiveness analysis of Option B+ for HIV prevention and treatment of mothers and children in Malawi. PLoS One 8: e57778. doi: 10.1371/journal.pone.0057778
[36]  Zulliger R, Black S, Holtgrave DR, Ciaranello AL, Bekker LG, et al. (2013) Cost-Effectiveness of a Package of Interventions for Expedited Antiretroviral Therapy Initiation During Pregnancy in Cape Town, South Africa. AIDS Behav.
[37]  Changala M, Kapyata H, Kahula M, Siachiwena C, Kalichini P, et al. (2012) Mothers’ confusions over the extended nevirapine regimen for HIV-exposed infants in resource-limited settings. 22–27 July 2012, XIX International AIDS Conference (Abstract LBPE30; http://wwwiasocietyorg/Defaultaspx?pageI？d=11&abstractId=200747587). Washington DC, USA.
[38]  Ishikawa N, Shimbo T, Miyano S, Sikazwe I, Ghidinelli MN, et al. (2012) Field effectiveness of WHO PMTCT guidelines in preventing postnatal HIV transmission in resource-limited settings: operational barriers and complexities related to the implementation of extended infant prophylaxis. 22–27 July 2012, XIX International AIDS Conference (Abstract TUPE177; http://wwwiasocietyorg/Defaultaspx?pageI？d=11&abstractId=200744282). Washington DC, USA.
[39]  Ishikawa N, Miyano S, Shimbo T (2011) Treating all HIV-infected pregnant women irrespective of CD4 count: missed opportunity for ART initiation during the prevention of mother-to-child transmission of HIV. 17–20 July 2011, 6th IAS Conference on HIV Pathogenesis and Treatment, (Abstract TULBPE056; http://wwwiasocietyorg/Defaultaspx?pageI？d=11&abstractId=200743928). Roma, Italy.
[40]  The Interagency Task Team (2013) Toolkit, Expanding and Simplifying Treatment for Pregnant Women Living with HIV: Managing the Transition to Option B/B+.
[41]  UNICEF (2013) Rapid Assessment of the 2010 WHO Guidelines in Four Countries: Lesotho, Malawi, the United Republic of Tanzania and Zambia. New York: UNICEF.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133